Biotechnology company Helaina is taking the next step in its mission to transform nutrition with human equivalent bioactive proteins by bringing its flagship ingredient â effera Human Lactoferrin â to market in the coming quarter with the help of a $45 million Series B fundraise and strategic partnerships with a handful of CPG companies and a distributor.
